Innovative immuno-therapy company welcomes former President and COO of Celgene

AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Scott Smith to the Board of Directors.

“We are thrilled to welcome Scott to the Triumvira Board of Directors,” said President and CEO of Triumvira Immunologics, Dr. Paul Lammers. “Scott’s leadership experience in immunology and oncology, together with his commercial operations expertise, will be instrumental as we build our company and work to bring new treatments to patients in need through our proprietary T Cell-Antigen Coupler (TAC) technology.”

Read Complete Article

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations

AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Donna Rill as Chief Technology Officer. As CTO, Rill will use her extensive technology development and manufacturing experience to help drive Triumvira’s clinical development programs.

Ms. Rill is an accomplished expert in cellular therapy manufacturing and has held responsibility for the design and qualification of cell and gene therapy laboratories using novel technologies, as well as production, service and research type laboratories. In addition to her construction, project management and regulatory/quality assurance and control knowledge, she brings extensive operational and strategic experience in cell and gene therapy, and antibody and protein production.

Read Complete Article